Endophthalmitis: prevention better than cure

Article

According to Zdenek Gregor of Moorfields Eye Hospital, London, UK, prevention of endophthalmitis will always be preferable to a cure. While the use of preoperative povidone iodine has managed to decrease the incidence of the infection, the hope is that per-operative intracameral antibiotics will further fuel a decrease in incidence of this worrying consequence of cataract surgery.

According to Zdenek Gregor of Moorfields Eye Hospital, London, UK, prevention of endophthalmitis will always be preferable to a cure. While the use of preoperative povidone iodine has managed to decrease the incidence of the infection, the hope is that per-operative intracameral antibiotics will further fuel a decrease in incidence of this worrying consequence of cataract surgery.

Speaking at the "Endophthalmitis following cataract surgery" symposium, Dr Gregor reminded his audience that the visual prognosis for postoperative endophthalmitis has improved dramatically since the 1960s. At that time, around 75% of cases resulted in a loss of hand motion visual acuity (HM), however, the prospects are now much brighter with vision of 6/12 or more being seen in between 53 to 90% of patients. This improvement came about when it was realised that damage to the posterior segment could be minimised with immediate administration of intravitreal antibiotics, with or without pars plana vitrectomy.

The pivotal Endophthalmitis Vitrectomy Study (EVS) of 1995 confirmed the value of this procedure, finding that the systemic use of the antiobiotics on the day was not useful whereas immediate vitrectomy yielded positive results, but only in those patients with the poorest visual function (<HM).

Dr Gregor then moved on to outline the most recent developments. Vitrectomy techniques have advanced considerably since the EVS report, and are much safer even in the absence of posterior vitreous detachment. Wide-angle viewing has allowed for larger laboratory samples, earlier and more extensive evacuation of causative organisms and toxins, greater access to the aqueous and for better distribution of injected antibiotics. In addition to these technical advancements developments in drug use has also had an impact. Intraocular steroids are gaining credibility as a method of reducing the effects of the inflammatory cytokines on the retina and new systemic antibiotics, such as fourth generation fluoroquinolones, are proving effective against Gram positive and negative organisms.

Dr Gregor's presentation supported the notion that prevention is indeed better than a cure, and with the evolution of a new generation of antibiotics and steroids, such as the per-operative intracameral antibiotics currently being tested in the ESCRS-sponsored study, the future of endophthalmitis treatment is looking promising.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.